Safety and Efficacy of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis

Kangstem Biotech

Status and phase: Completed; Phase 2; Phase 1

Conditions: Rheumatoid Arthritis

Treatments: Other: sterile saline; Biological: FURESTEM-RA Inj

Study type: Interventional

Funder types: Industry

Identifiers

NCT03618784

K0202

Details and patient eligibility

About

Safety and Efficacy of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid arthritis

Full description

Phase 1: Single center, open Phase 2a : Multi-center, randomized, double-blind, parallel, placebo Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-RA Inj. for Moderate to Severe Rheumatoid arthritis

Enrollment: 33 patients

Sex: All

Ages: 19 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. of either gender, 19-80years old

2. Subjects must be diagnosed according to the 2010 ACR/EULAR criteria for at least 12 weeks duration.

3. Subjects must be diagnosed with ACR functional class I. II, III

4. ≥ 6 tender joints, swollen joints (68 joint count) at Screening

5. Subject who has moderate to severe disease activity (DAS28-ESR>3.2) on screening visit

6. History of treatment for one of conventional DMARDs or biologic DMARDs or JAK inhibitors AND people diagnosed with either (a) or (b) by a trained person, or people that have potential side effects thus not qualified from using biologic DMARDs.

   1. people that have no effect with permitted dose taking for more than 3 months
   2. people with a history of side effects of relevant treatment

7. Subjects must be taking cDMARDs(including methotrexate, sulfasalazine, hydroxychloroquine, leflunomide) or tacrolimus of stable dose More than 12 weeks before baseline visit and be willing to remain on stable dose throughout the study

8. If subject is currently administering steroids everyday, when steroid dose is converted into prednisolone oral dose, the subject should take a stable dose(≤10mg/day) over 4 weeks on screening visit

9. In case of taking NASAIDs, Tramadol patients with stable amount of medication at least 2 weeks before screening visit.

10. During screening visit , patients with an ESR result of 28mm/hr; patients with a 1.0mg/dL or greater in a CRP testing

11. Subject who understands and voluntarily sign an informed consent form

Exclusion criteria

1. Subjects who is diagnosed ACR function class IV Rheumatoid Arthritis

2. Patients who are judged by the PI(or Sub-I) to be unable to participate in clinical trials due to uncontrolled or unstable cardiovascular disease or severe blood disease

3. Subjects who has AIDS, other rheumatic disease(Crohn's disease, systemic lupus erythematosus, lyme disease, psoriatic arthritis, spondylarthropathy, infectious or reactive arthritis, reiter's syndrome, etc.)

4. Prior use of bDMARDs, within the following windows prior to baseline

   • 24 weeks for Rituximab
   • 10 weeks for Abatacept, Golimumab, Certolizumab pegol, Tocilizumab
   • 7 weeks for Infliximab
   • 4 weeks for Etanercept
   • 3 weeks for Tofacitinib, Baricitinib

5. Subject who has history of hypersensitivity, heavy metal poisoning, etc. to drugs which is composed of similar components.

6. Subject who has treated intravenous, intramuscular steroid injection within 2 weeks before screening visit or intra-articular steroid injection within 4 weeks before screening visit

7. Subject who has administered ACTH(adrenocorticotropic hormone) agents within 4 weeks before screening visit

8. Subject who has undergone administration of any investigational drug within 30 days before screening visit.

9. Use of prohibited medication or inability to avoid the use of prohibited medication during the study

10. Pregnant, breast-feeding women

11. A female or male in their childbearing ages that is not willing to take proper contraceptive methods during a study

12. Subject who has sever dyshepatia (Serum creatinine level ≥ 1.7mg/dl)

13. Subject who has severe renal dysfunction (ALT/AST/bilirubin value ≥ 2 upper limit of the normal range at screening test)

14. Any other condition which the PI Judges would make patient unsuitable for study participation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

33 participants in 2 patient groups, including a placebo group

FURESTEM-RA Inj.

Experimental group

Treatment:

Biological: FURESTEM-RA Inj

Placebo Comparator: Placebo

Placebo Comparator group

Treatment:

Other: sterile saline